 |
Journal articles
Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.
Annie Brion
1
Béatrice Mahé
2
Brigitte Kolb
3
Bruno Audhuy
4
Philippe Colombat
5
Hervé Maisonneuve
6
Charles Foussard
7
A. Bureau
1
Christophe Ferrand
1
Jean-François Lesesve
8
Marie-Christine Béné
9
Pierre Feugier
8, 9
Christophe Ferrand 1
Author
Jean-François Lesesve 8
Author
Marie-Christine Béné 9
Author
Pierre Feugier 8, 9
Author
1
Service d'hématologie (France)
2
Service d'Hématologie (44093 Nantes - France)
- CHU Nantes - Centre hospitalier universitaire de Nantes (1 Place Alexis-Ricordeau, 44000 Nantes - France)
3
Service d'Hématologie (Reims - France)
- CHU Reims - Centre Hospitalier Universitaire de Reims (45, rue Cognacq-Jay 51100 Reims - France)
5
Service d'hématologie [Tours] (France)
7
Service d'hématologie (Angers - France)
- CHU Angers - Centre Hospitalier Universitaire d'Angers (4 rue Larrey - 49933 Angers cedex 9 - France)
- Hôtel Dieu (France)
8
Service d'Hématologie [CHRU Nancy] (Technopôle Nancy-Brabois, Rue du Morvan, 54500 Vandœuvre-lès-Nancy - France)
- CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy (Siège social : 29 avenue du Maréchal de Lattre de Tassigny, CO 60034, 54035 NANCY CEDEX Hôpital Central : 29 Avenue du Maréchal de Lattre de Tassigny, 54035 Nancy Hôpitaux de Brabois / Enfants : Rue du Morvan, 54500 Vandœuvre-lès-Nancy Maternité régionale :10 Avenue Dr Heydenreich, 54000 Nancy - France)
9
RHEM - Relations Hôte-Environnement (Université Henri Poincaré, Faculté de Médecine, av de la Forêt de Haye, 54500 Vandoeuvre-les-Nancy - France)
- UHP - Université Henri Poincaré - Nancy 1 : EA4369 (24-30 rue Lionnois, BP 60120, 54 003 NANCY cedex, France - France)
Abstract : The relevance of high-dose chemotherapy followed by auto-SCT in CLL remains to be defined. The aim of the prospective, randomized, GOELAMS LLC 98 trial was to compare two strategies in previously untreated CLL patients aged <60 years. Conventional chemotherapy (Arm A) consisted of six monthly courses of CHOP followed by six CHOP courses in every 3 months in those achieving a complete or PR. Arm A was compared with high-dose therapy with auto-SCT (Arm B), used as consolidation after three CHOP courses in case of CR or very good PR. A total of 86 patients were enrolled, of which 39 and 43 patients were evaluable in arm A and arm B, respectively. The primary endpoint was PFS. On an intent-to-treat basis and with a median follow-up time of 77.1 (range 1-135.5) months, the median PFS was 22 months in Arm A and 53 months in Arm B (P<0.0001). Median survival time was 104.7 months in arm A and 107.4 months in arm B. This trial demonstrates that frontline high-dose therapy with auto-SCT prolongs PFS but does not translate into a survival advantage in advanced CLL patients in the pre-rituximab era.
Document type :
Journal articles
Domain :
Complete list of metadata
https://www.hal.inserm.fr/inserm-00821100
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 7, 2013 - 2:34:00 PM
Last modification on : Sunday, October 25, 2020 - 7:07:55 AM
Contributor : Philippe Saas <>
Submitted on : Tuesday, May 7, 2013 - 2:34:00 PM
Last modification on : Sunday, October 25, 2020 - 7:07:55 AM
Links full text
Identifiers
- HAL Id : inserm-00821100, version 1
- DOI : 10.1038/bmt.2011.117
- PUBMED : 21725374
Collections
Citation
Annie Brion, Béatrice Mahé, Brigitte Kolb, Bruno Audhuy, Philippe Colombat, et al.. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.. Bone Marrow Transplantation, Nature Publishing Group, 2012, 47 (4), pp.542-8. ⟨10.1038/bmt.2011.117⟩. ⟨inserm-00821100⟩
Metrics
Record views